ELC : Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, February 20, 2012

ELC : Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies



  Blogger's Note: requires registration


CME expires 2013

Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies

Preclinical and clinical investigations provide a strong rationale for the use of angiogenesis inhibitors in ovarian primary peritoneal/fallopian tube cancer, and a large variety of angiogenesis inhibitors are in late stages of development. Drs. Thomas Herzog and Robert Burger discuss VEGF and VEGFR inhibitors including emerging data from clinical trails, management of toxicities and the future direction of this field.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.